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ASS1 Overexpression: A Hallmark 
of Sonic Hedgehog Hepatocellular 
Adenomas; Recommendations for  
Clinical Practice
Margaux Sala ,1 Delphine Gonzales ,2 Thierry Leste-Lasserre ,2 Nathalie Dugot-Senant,3 Valérie Paradis ,4  
Sylvaine Di Tommaso ,1,5 Jean-William Dupuy ,6 Vincent Pitard ,7 Cyril Dourthe ,1,5 Amedeo Sciarra ,8  
Christine Sempoux,8 Linda D. Ferrell,9 Andrew D. Clouston,10 Gregory Miller,10 Mathew M. Yeh,11 Swan Thung,12  
Annette S.H. Gouw,13 Alberto Quaglia,14 Jing Han,15 Ji Huan,15 Cathy Fan,16 James Crawford,16 Yasuni Nakanuma,17  
Kenichi Harada,18 Brigitte le Bail ,1,19 Claire Castain ,19 Nora Frulio ,20 Hervé Trillaud ,20,21 Laurent Possenti,22 
Jean-Frédéric Blanc ,1,22 Laurence Chiche ,23 Christophe Laurent,23 Charles Balabaud ,1 Paulette Bioulac-Sage ,1  
Anne Aurélie Raymond ,1,5* and Frédéric Saltel 1,5*
Until recently, 10% of hepatocellular adenomas (HCAs) remained unclassified (UHCA). Among the UHCAs, the sonic 
hedgehog HCA (shHCA) was defined by focal deletions that fuse the promoter of Inhibin beta E chain with GLI1. 
Prostaglandin D2 synthase was proposed as immunomarker. In parallel, our previous work using proteomic analysis 
showed that most UHCAs constitute a homogeneous subtype associated with overexpression of argininosuccinate syn-
thase (ASS1). To clarify the use of ASS1 in the HCA classification and avoid misinterpretations of the immunohisto-
chemical staining, the aims of this work were to study (1) the link between shHCA and ASS1 overexpression and (2) 
the clinical relevance of ASS1 overexpression for diagnosis. Molecular, proteomic, and immunohistochemical analyses 
were performed in UHCA cases of the Bordeaux series. The clinico-pathological features, including ASS1 immuno-
histochemical labeling, were analyzed on a large international series of 67 cases. ASS1 overexpression and the shHCA 
subgroup were superimposed in 15 cases studied by molecular analysis, establishing ASS1 overexpression as a hallmark 
of shHCA. Moreover, the ASS1 immunomarker was better than prostaglandin D2 synthase and only found positive in 
7 of 22 shHCAs. Of the 67 UHCA cases, 58 (85.3%) overexpressed ASS1, four cases were ASS1 negative, and in five 
cases ASS1 was noncontributory. Proteomic analysis performed in the case of doubtful interpretation of ASS1 over-
expression, especially on biopsies, can be a support to interpret such cases. ASS1 overexpression is a specific hallmark 
of shHCA known to be at high risk of bleeding. Therefore, ASS1 is an additional tool for HCA classification and 
clinical diagnosis. (Hepatology Communications 2020;4:809-824).
Hepatocellular adenomas (HCAs) are rare benign liver tumors. The main risk factor is hormonal exposure to either estrogens or androgens,(1,2) but metabolic, vascular diseases, glycogen storage diseases, and some other rare genetic diseases have also been associated with HCA development.(3-5) 
Abbreviations: ASS1, argininosuccinate synthase 1; b-HCA, beta-catenin mutated hepatocellular adenoma; b-IHCA, beta-catenin mutated and 
inflammatory hepatocellular adenoma; BMI, body mass index; cDNA, complementary DNA; CRP, C-reactive protein; GS, glutamine synthase; 
HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; H&E, hematoxylin and eosin stain; H-HCA, HNF1A mutated hepatocellular 
adenoma; HHIP, hedgehog interacting protein; HNF1A, hepatocyte nuclear factor 1 A; IHC, immunohistochemistry; IHCA, inflammatory HCA; 
INHBE, inhibin beta E chain; LFABP, liver fatty acid binding protein; mRNA, messenger RNA; MS, mass spectrometry; NT, nontumoral; OC, oral 
contraception; PCR, polymerase chain reaction; Ppia, peptidyl propyl isomerase A; PTCH1, patched homolog 1 (Drosophila); PTGDS, prostaglandin 
D2 synthase; RT-PCR, reverse-transcription PCR; Rpl13a, ribosomal protein L13a; SAA, serum amyloid A protein; shHCA, sonic hedgehog 
hepatocellular adenoma; T, tumoral; UHCA, unclassif ied hepatocellular adenoma.
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Bleeding and malignant transformation into hepatocel-
lular carcinoma (HCC) are the two major complications, 
both of which are strongly related to the size of the ade-
noma. Accordingly, clinical guidelines recommend liver 
resection when the HCA reaches 5 cm.(6-11) HCAs rep-
resent a heterogeneous entity divided into several sub-
types based on their patho-molecular features: H-HCA 
with inactivating mutations of the hepatocyte nuclear 
factor 1 A (HNF1A) gene, inflammatory HCA (IHCA) 
with diverse mutations leading to the activation of 
STAT3, b-HCA with mutations in the CTNNB1 gene, 
leading to activation of the beta-catenin pathway, and 
unclassified HCAs (UHCAs), which represent 10% of 
all HCAs(3,12) and are the focus of the current study.
In the pathological diagnostic workup, molecu-
lar analyses are rarely performed, and HCA subtype 
identification is based on their prototypical protein 
expression at immunohistochemistry (IHC). Accordingly, 
loss of liver fatty acid binding protein (LFABP), aber-
rant expression of C-reactive protein (CRP), and glu-
tamine synthase (GS) are used to identify H-HCA, 
IHCA, b-HCA and b-IHCA, respectively.(13-17) Until 
now, HCAs were classified as UHCAs when all of these 
immunohistochemical markers were negative.
Recently, a new molecular subgroup represent-
ing 4% of all HCAs, the sonic hedgehog HCA 
(shHCA), has been described, and was associated 
with a high rate of bleeding.(18) These tumors are 
characterized by focal deletions that fuse the pro-
moter of inhibin beta E chain (INHBE) with GLI1, 
inducing the up-regulation of GLI expression 
and an associated signature (patched homolog 1 
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[Drosophila] [PTCH1], prostaglandin D2 synthase 
[PTGDS], hedgehog interacting protein [HHIP]) 
assigned to the sonic hedgehog pathway activa-
tion. These molecular data have been obtained on 
tumors’ complementary DNA (cDNA), requiring a 
good quality of messenger RNA (mRNA) on frozen 
tissue, a biological material often unavailable in rou-
tine practice. Prostaglandin D2 synthase (PTGDS) 
has been proposed as an immunomarker to identify 
shHCA.(18) However, the use of PTGDS has not 
been validated.(16,18,19)
At the same time, using proteomic analysis, we 
identified a homogeneous subgroup of UHCA,(20) 
also associated with a high rate of bleeding, and 
characterized by the overexpression of argininosuc-
cinate synthase (ASS1) protein(20) in comparison 
with nontumoral (NT) liver. ASS1 positivity without 
overexpression in different HCA subgroups has been 
reported and has created confusion about the perti-
nence of ASS1 as an immunomarker.(19,21)
Our aims were (1) to study the link between 
shHCA and ASS1 overexpression, (2) to clarify the 
use of ASS1 as an immunomarker and avoid misin-
terpretations of the staining, through the study of a 
large series of UHCA cases, and (3) to propose rec-




We defined UHCA, from the IHC analysis, using 
the main HCA immunomarkers (LFABP-positive, 
GS and CRP and/or serum amyloid A protein 
[SAA]–negative). UHCAs were collected from three 
different sources:
1. 24 surgical cases retrieved in the Pathology depart-
ment, CHU Bordeaux (from our series of 224 re-
sected HCAs); of the 24 cases, 17 were previously 
published as UHCA, defined by molecular analysis 
before the discovery of shHCA,(20) and 12 of 17 
had been further classified by molecular analysis as 
shHCA ( J.Z-R.);
2. 17 surgical cases sent for advice to the Pathology 
department, CHU Bordeaux; these 17 consults 
were defined according to strict IHC criteria, all 
HCA immunomarkers being entirely negative. 
Since the work of Hale et al.,(22) great progress has 
been made in GS interpretation using molecular 
biology as the gold standard(23); a strictly normal 
GS expression allowed us to exclude a b-catenin 
mutation.
3. 32 cases from an international (Europe, United 
States, Asia, and Australia) cooperation study on 
UHCA. For this latter source, we requested liver 
pathologist colleagues to send at least one he-
matoxylin and eosin (H&E) and one blank slide 
with tumoral (T) and NT tissue; we excluded 
six cases (poor fixation, GS positivity, or unsure 
diagnosis of HCA in one, two, and three cases, 
respectively).
Finally, a total of 67 cases were used in the study.
H&E slides were reviewed by an experienced liver 
pathologist (P.B.S.). In addition to H&E and ASS1, 
other stainings (HCA markers, CD34, CK7, and 
reticulin) were analyzed in all cases from Bordeaux 
and in other cases when there were available slides.
We first selected cases in three groups based on 
the H&E slides. Cases were considered as (1) “com-
patible” with the diagnosis of shHCA, using the 
criteria already defined(20) (primarily a characteristic 
bland aspect), (2) “in favor of the diagnosis” when 
there were additional blood cavities at different 
stages of degradation, or (3) “not compatible” when 
there were pathological criteria usually observed in 
H-HCA, IHCA, b-HCA, b-IHCA, or possibly in 
Focal Nodular Hyperplasia (FNH).
We analyzed the pathological criteria of the tumor 
as well as the percentage rate of steatosis in the NT 
liver. In addition, for the cases of CHU Bordeaux, we 
analyzed the link between the mode of discovery and 
the presence of hemorrhagic/necrotic tissue (cases 
from abroad, with missing clinical data could not be 
used for this point).
As far as possible, we collected the following 
clinical criteria: age, sex, oral contraception (OC), 
body mass index (BMI), number of nodules, size of 
the largest nodule, mode of discovery, and associated 
diseases.
All patients have given informed consent, and 
this study was approved by the local committee 
“Direction de la Recherche Clinique et de l’Innova-
tion” of Bordeaux University Hospital, Bordeaux Liver 
Biobank BB-0033-00036.




Surgical specimens were fixed in 10% buffered 
formaldehyde; tissue sections from T and NT paren-
chyma were routinely processed for the purpose of 
diagnosis. Selected representative slides, including T 
and NT tissue, were processed for ASS1 and PTGDS 
IHC.
For ASS1 immunostaining, the 2.5-µm-thick 
sections were dewaxed and rehydrated, and antigen 
retrieval was performed in the PT Link pH 9 buf-
fer (Agilent Dako, Santa Clara, CA) for 40  minutes 
at 95°C then cooled down to 65°C for 20  minutes. 
All staining procedures were performed in an auto-
mated autostainer (Agilent Dako) using the Kit Flex 
(Agilent Dako) reagents according to the manufac-
turer’s instructions. The sections were incubated with 
the ASS1 rabbit polyclonal antibody (16210-1-AP; 
ProteinTech, Rosemont, IL) at a 1:1,000 dilution 
for 45 minutes at room temperature. The slides were 
finally counterstained with hematoxylin, dehydrated, 
and mounted. Each immunohistochemical run con-
tained a negative control (buffer, no primary antibody). 
Sections were visualized with a Nikon Eclipse501 
microscope, and images were acquired using NIS-
Elements F.
UHCA overexpressing ASS1 in the tumor 
(either homogeneous or heterogeneous) but more 
than in the corresponding NT liver was classified 
as HCA ASS1+. More precisely, ASS1 overexpres-
sion means higher signal in the tumor, and over-
all there is loss of the zonal distribution usually 
observed in NT liver. Cases with no tumoral stain-
ing or less staining than in the nontumoral liver 
were considered as HCA ASS1 negative. Cases 
with difficulty in defining for any reason the dif-
ference between T and NT liver were considered as 
“noncontributory.”
PTGDS immunostaining was performed in a ref-
erence center (Hospital Beaujon, Paris, France) on 
blank slides from Bordeaux series. Antigen retrieval 
was performed with the CC1 buffer (pH 8.4; Roche, 
Basel, Switzerland); anti-PTGDS (clone HPA004938; 
Sigma-Aldrich, St. Louis, MO) was used at a 1:25 
dilution.
Interpretation was made by an experienced pathol-
ogist (V.P.) as positive (intensity mild [1] or moderate 
[2], diffuse, or focal) or negative.
moleCulaR analysis
mRna isolation
Frozen tissue from T and NT livers was obtained 
immediately after surgery and stored at −80°C until 
used. Total RNA from samples was homogenized in 
Tri-reagent (Euromedex, Strasbourg, France), and 
RNA was isolated using a standard chloroform/ 
isopropanol protocol.(24) RNA was processed and 
analyzed following an adaptation of published 
methods.(25) Concentration of the total RNA sam-
ples was measured using the microDrop DS-11 
Spectrophotometer (DeNovix Inc., Wilmington, 
DE). The purity of total RNA was also assessed 
using an Agilent TapeStation 2200 (Agilent 
Technologies, Palo Alto, CA).
mRna Retrotranscription
cDNA was synthesized from 2  μg of total RNA 
using RevertAid Premium Reverse Transcriptase 
(Fermentas, Waltham, MA) and primed with oligo-dT 
primers (Fermentas) and random primers (Fermentas).
polymerase Chain Reaction
Samples were genotyped from cDNA by poly-
merase chain reaction (PCR) using primers men-
tioned in Nault et al.(18) PCR assay was carried out 
on a Bio-Rad C1000 thermal cycler (Hercules, XA) 
(10-µL volume) using 4 ng of cDNA, GoTaq G2 Hot 
Start Green Master Mix (Promega, Madison, WI), 
and 0.2 µM of each primer. PCR conditions were as 
follows: 1 cycle, 5 minutes at 95°C; 37 cycles, 30 sec-
onds at 95°C, 30 seconds at 58°C, and 45 seconds at 
72°C; 1 cycle, 5 minutes at 72°C. PCR products were 
analyzed on a Labchip GX microfluidic electropho-
resis system (PerkinElmer, Waltham, MA) using the 
DNA5k kit.
Quantitative pCR
Quantitative PCR was performed using a 
LightCycler 480 Real-Time PCR System (Roche, 
Meylan, France). Quantitative PCR reactions were per-
formed in duplicate for each sample, using transcript- 
specific primers, cDNA (4  ng), and LightCycler 480 
SYBR Green I Master (Roche) in a final volume of 
10 μL. The quantitative PCR data were exported and 
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analyzed using software (Gene Expression Analysis 
Software Environment) developed at the Neurocentre 
Magendie (Bordeaux, France). To determine the refer-
ence gene, the Genorm method was used.(25) Relative 
expression analysis was normalized using two reference 
genes. Ribosomal protein L13a (Rpl13a) and peptidyl 
propyl isomerase A (Ppia) genes were used as the ref-
erence genes. The relative level of expression was then 
calculated using the comparative (2−∆∆CT) method.(26) 
Primer sequences are provided in Supporting Table S1.
Digital PCR, in vitro analysis methods, enzyme-
linked immunosorbent assay (ELISA), and pro-
teomic analysis were performed as described in the 
Supporting Information.
Results
To determine whether shHCA and ASS1 overex-
pression in HCA superimposed or overlapped, we used 
UHCA cases of the Bordeaux cohort for performing 
molecular, immunopathological, and clinical analyses.
moleCulaR ClassiFiCation
We searched for the focal deletions fusing the pro-
moter of INHBE with GLI1, defining the shHCA. 
As described by Nault et al.,(18) we performed PCR on 
the cDNA of frozen T and corresponding NT tissues. 
We analyzed 19 tumors from 16 of 24 patients with 
UHCA diagnosis based on H&E and IHC criteria. For 
the other 8 patients, we did not have frozen tissue. We 
amplified the corresponding amplicons in 12 tumors, 
indicating the deletion. We had no amplification for 
seven tumors (Table 1 and Supporting Fig. S1).
Thus, to complete this approach, we also analyzed the 
mRNA expression of the shHCA gene signature (GLI, 
PTCH1, PTGDS, and HHIP)(18) from frozen tissues 
of the same 19 tumors by quantitative reverse-transcrip-
tion PCR (RT-PCR). In three cases, the GLI cDNA 
taBle 1. moleCulaR analysis oF tHe 24 uHCa Cases oF BoRDeauX
Case Tumor
Detection of a Deletion Fusing the 
Promoter of INHBE With GLM Gene
mRNA Expression (T:NT Ratio)
mRNA Expression 
(T:NT Ratio)
GLI1 PTCH1 PTGDS HHIP ASS1
105 Positive 12,70 11,73 99,20 8,23 7,53
178 Positive 8,42 4,58 0,03 0,50 7,91
70 Positive 5,54 16,56 140,48 2,74 4,80
168 Negative 66,65 1,98 290,71 2,23 11,07
121 Negative 6,92 8,52 51,82 3,64 7,04
37 Negative 1,89 2,06 9,41 0,89 2,71
162 T1 Positive 9,63 3,41 44,80 20,40 7,92
162 T2 Positive 11,49 20,13 89,34 46,08 7,17
162 T3 Positive 11,49 10,58 92,26 35,45 7,17
183 Positive 10,97 only T 1234,65 12,86 12,86
176 Negative 26,58 5,51 187,05 2,20 10,00
175 Positive 111,89 7,83 179,09 0,52 1,89
209 Positive 4,26 7,19 39,31 22,11 17,41
217 Positive 2,81 0,80 89,06 only NT 2,04
242 T1 Positive 6,84 30,26 1,29 5,71 2,73
242 T2 Negative 10,96 22,32 2,26 2,49 2,60
237 Positive 7,81 87,97 3,52 13,90 2,72
235 Negative 15,92 3,42 0,65 6,88 3,04
244 Negative 0,06 0,02 0,43 0,31 0,49
Notes: T:NT ratios were calculated from quantitative RT-PCR data. Results that identify a shHCA are highlighted: ratios between 2 and 
5 are highlighted in light brown and ratios ≥5 are highlighted in dark brown. “only T” or “only NT” indicate that mRNA was detected 
only in liver T or NT, respectively.
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quantity was insufficient for the NT part. For these cases, 
we performed digital PCR to assess the T:NT mRNA 
expression ratios. GLI mRNA overexpression was con-
firmed in the 12 tumors in which the focal deletions 
were detected, and more widely in 18 of 19 tumors. The 
other shHCA signature genes were not systematically 
associated to a GLI overexpression (16 of 19 tumors for 
PTCH1, 15 of 19 tumors for PTGDS, 14 of 19 tumors 
for HHIP, and 11 of 19 tumors positive for the four 
biomarkers of the shHCA signature) (Table 1).
In parallel, we analyzed the ASS1 mRNA expres-
sion in the same tumors. ASS1 was overexpressed 
in the 12 tumors for which the focal deletions were 
detected, and was more widely strictly associated with 
GLI overexpression (18 of 19 tumors) (Table 1).
Taken together, both GLI and ASS1 were over-
expressed in shHCAs. Subsequently, we investigated 
whether GLI and ASS1 overexpression in shHCA 
was associated. To verify this hypothesis, we performed 
Shapiro and linear regression statistical tests. Residual 
values did not follow a normal distribution (P = 0.1278) 
(Supporting Fig. S2A). In the same way, the linear 
regression analysis did not demonstrate a significant 
association (Supporting Fig. S2B). PTGDS overex-
pression also was not significantly associated with GLI 
overexpression (P = 0.5938) (Supporting Fig. S2C,D).
We also investigated whether there was any func-
tional link between GLI and ASS1. To do this, we first 
tested GLI expression levels in three HCC cell lines 
(Huh7, HepG2, and SNU398) and one hepatocyte 
cell line (THLE2). We observed significant variation 
in GLI expression. Among the three HCC cell lines, 
we first selected the SNU398 cells, which strongly 
expressed GLI (Supporting Fig. S3A), and we depleted 
GLI with siRNA without inducing any change in 
ASS1 expression (Supporting Fig. S3B). To mimic the 
overexpression of GLI in shHCAs, we overexpressed 
a hemagglutinin-tagged GLI by transient transfec-
tion of an expression plasmid in HUH7 (Supporting 
Fig. S3C) and SNU398 cells (Supporting Fig. S3D). 
As expected, GLI overexpression induced an up- 
regulation of one of its target vimentin(27) in both cell 
lines but without any change in ASS1 (Supporting 
Fig. S3C,D). We then selected HepG2 and SNU398, 
which expressed INHBE and showed that its deple-
tion had no effect on ASS1 expression (Supporting 
Fig. S4A,B). Despite the fact that both GLI and ASS1 
overexpressed in shHCA, we did not observe a direct 
molecular link between GLI and ASS1.
speCiFiCity oF ass1 
oVeReXpRession FoR 
iDentiFying shHCa
As already shown by IHC and western blot anal-
yses of ASS1 on the different HCA subtypes,(20) it 
is possible to find a positivity of ASS1 in the tumor 
that must be differentiated from overexpression in the 
tumor compared with the NT liver, which is specific 
to shHCA. To further support this outcome, we quan-
tified the T:NT ratio in the different HCA subgroups 
using mass spectrometry. We analyzed 41 HCAs 
representing all subtypes (9 shHCAs, 3 H-HCAs, 3 
IHCAs, 5 b-HCA exon 3 non S45s, 6 b-HCA exon 
3 S45s, 6 b-HCA exon 7/8s, 3 b-IHCA exon 3 non 
S45s, 3 b-IHCA exon 3 S45s, and 3 b-IHCA exon 
7/8s) and three focal nodular hyperplasia (HNF). 
ASS1 is overexpressed in all cases of shHCAs and in 
none of the other subtypes of HCA or FNH (Fig. 1). 
These data confirmed that ASS1 overexpression in 
the tumor is a specific characteristic of shHCA.
CompaRison oF shHCa 
iDentiFiCation peRFoRmanCe 
By ass1 anD ptgDs
Next, we compared the performance of ASS1 and 
PTGDS as immunomarkers. We performed ASS1 IHC 
on the 24 UHCA of the Bordeaux series. As described 
in Henriet et al.,(20) we evaluated the ASS1 overexpres-
sion in the tumor in comparison with adjacent NT liver. 
ASS1 was overexpressed in tumor in comparison with 
NT liver in 23 of 24 cases. The staining was diffuse 
(>80%) on the whole tumor in 13 cases or heteroge-
neous in 10 cases; however, in all cases the overexpres-
sion T:NT ratio was clear (Figs. 2-4). The last case 
was excluded from the diagnosis of shHCA, as ASS1 
was strongly expressed in NT liver at the same level 
of the tumor (interpreted as noncontributory). It has 
to be underlined that this last case (case 244) was the 
same that was shHCA negative in molecular analysis 
(Table 1). Therefore, 23 of 24 (95.8%) of the UHCA 
Bordeaux cohort overexpressed ASS1 (Figs. 2B and 4A).
In parallel, PTGDS was performed in the Beaujon 
Reference Center (France) on 22 cases of the 
Bordeaux cohort (25 slides, as two different tumors 
were tested in the three cases that were all already 
positive for ASS1). Seven cases (31.8%) were inter-
preted as positive (8 of 25 tumors). Three cases (four 
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tumors) were diffusely positive (mild or moderate 
intensity); in four additional cases, the staining was 
mild and focal. Fifteen cases (68.2%) already positive 
for ASS1 were PTGDS-negative (Fig. 2). Among 
the seven PTGDS-positive cases, five were demon-
strated as shHCA by molecular analysis and two were 
not tested. Among the 15 PTGDS-negative cases, 13 
were demonstrated as shHCA by molecular analysis 
and two were not tested (Table 1 and Fig. 2).
Finally, ASS1, strictly interpreted as an overex-
pression in comparison with NT liver, was the best 
immunomarker to identify shHCA. Due to the fact 
that the 23 cases were positive for ASS1 (and negative 
for other HCA biomarkers), in addition to the evi-
dence collected by molecular and proteomic analyses, 
we classified these 23 cases as shHCA.
patHologiCal FeatuRes
In the cohort of 24 Bordeaux shHCA cases, 23 
shared the H&E characteristics already published as 
ASS1+HCA(20): well differentiated, nonencapsulated 
hepatocellular proliferation, with bland aspect and com-
posed of clear cells often associated with hypereosino-
philic and packed cells related to ischemia, defining a 
compatible aspect (Fig. 3). In 6 of the 23 cases, there 
were additional pathological features not described in the 
original paper, namely, blood cavities at different stages 
of degradation (i.e., from cavities filled of red blood cells 
or with fibrillar material to quasi empty holes) and vas-
cular abnormalities with detachment of hepatocytes row 
from the vascular wall. These additional criteria, when 
present, help to classify shHCA.
CliniCo-patHologiCal 
CRiteRia
Regarding the Bordeaux series, all 23 cases (Table 2A 
and Supporting Table S2) occurred in women with a 
mean age of 40, on long-term OCs , with a median 
BMI of 28.7. The tumor was single in 10 cases and 
multiple in 13 cases (2 adenomatosis). The mean size of 
the largest nodule was 7 cm; in 7 cases the size was less 
than 5 cm. One to several manifestations of the meta-
bolic syndrome such as arterial hypertension, diabetes, 
dyslipidemia, and occasionally nonalcoholic steatohep-
atitis were observed in 11 cases, as a single manifes-
tation in six cases or triple in five cases, respectively. 
Steatosis in the NT liver was observed in 17 of the 23 
cases and was severe (over 60%) in seven cases. Reasons 
for admission to hospital varied (Supporting Table S2). 
In six cases, patients were admitted in emergency; in 11 
Fig. 1. ASS1 T versus NT liver expression ratio in HCA subtypes quantified by mass spectrometry. The red line indicates T/NT ratio = 1.
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cases they consulted for pain from mild to acute; and in 
six cases they were admitted for various conditions from 
check-up, such as raised gamma glutamine transferase 
to fortuitous discovery. There was no strict relationship 
between the mode of discovery and the observed liver 
damage, probably due in part to the delay between the 
detection of the nodule(s) and surgery (few days to 
close to 2 years) or autopsy in one case (few hours). 
For example, in the six cases discovered without pain, 
there was a small intratumoral hematoma in one case. 
The liver was close to normal in one case (178), with 
remnants of hemorrhagic areas in two cases (cases 
173 and 184), hemorrhagic foci at different stages in 
five cases (cases 37, 68, 162, 237, 242), hematoma at 
different stages in eight cases (cases 44, 66, 121, 176, 
187, 191, 217, and 235), hemorrhagic rupture in four 
cases (cases24, 70, 183, and 209), and with more or less 
extended areas of hemorrhagic necrosis in three cases 
(cases 105, 107, and 168).
In four cases with multiple nodules, there were 
worrisome criteria with areas of reticulin loss, cytolog-
ical atypia, and presence of pseudo glands; this led to 
the diagnosis of “borderline” tumors with even areas 
of malignant transformation in two cases.
ass1 ValiDation in a laRge 
CoHoRt
To test more broadly the performance of ASS1 
as an immunomarker, we increased the Bordeaux 
Fig. 2. Comparative analysis of PTGDS and ASS1 IHC of shHCA. (A) Comparative IHC of three different cases (cases 66, 242, 
and 178) with anti-PTGDS (left) and ASS1 (right) antibodies. PTGDS staining is interpreted as diffuse/moderate (a), mild intensity 
(c) or negative (e); ASS1 is clearly overexpressed in the three corresponding cases (b,d,f ), contrasting with NT liver. (B) Summary of 
comparative IHC results on the 22 shHCA cases of the Bordeaux cohort (24 tumors). PTGDS labeling intensity: mild (1), moderate (2), 
and focal (f). ASS1 labeling: homogeneous (H) and heterogeneous (h).
A B
Hepatology CommuniCations, Vol. 4, no. 6, 2020 SALA ET AL.
817
Fig. 3. Histology and IHC of shHCA (surgical specimens). (A) H&E is compatible/typical with the diagnosis of shHCA; tumor (T) is 
a well-differentiated, nonencapsulated hepatocellular proliferation with bland aspect, contrasting with steatotic (a) or nonsteatotic (b) NT 
liver; T consists of clear cells (c) often associated with hypereosinophilic and packed cells related to ischemia (d), blood cavities at different 
stages of degradation (e-h), damaged vascular wall with detachment from hepatocytes row (i), red blood cells (asterisk) and fibrous bands 
(arrows) related to remodeling of the tumor (j). (B) Typical ASS1 staining on NT liver (“honey comb”) (a) and on T liver: diffuse (b) or 
heterogeneous (c,d). Scale bars represent original magnification; when the bar is missing, magnification is ×1.
Hepatology CommuniCations, June 2020SALA ET AL.
818
collection of UHCA from two different sources: 
CHU Bordeaux consultations (17 cases) and interna-
tional cooperation study (26 cases) (Fig. 4A).
Considering all 67 cases, on H&E staining, 18 
were typical, 46 were compatible, and 3 were not 
compatible with the shHCA diagnosis (Fig. 4B). In 
total, ASS1 was overexpressed in 58 of the 67 cases 
(86.6%); 4 of the 67 (6.0%) were ASS1 negative; and 
5 of 67 (7.5%) were noncontributory (Fig. 4C). We 
performed an accuracy test that allowed us to estimate 
the sensitivity of ASS1 to 90.6%.
As illustrated in Table 2B,C, the global clinical data 
and the individual data in consultation and international 
cases (Supporting Table S3) were close to the data from 
CHU Bordeaux (Table 2A and Supporting Table S2).
uHCa anD unClassiFieD Cases
One of 24, 2 of 17, and 6 of 26 cases from CHU 
Bordeaux, consultations and international study, 
respectively, were not identified as shHCA (Fig. 4A). 
H&E, ASS1 IHC, and clinical data are presented in 
Supporting Table S4. Of these nine cases, four were 
ASS1-negative, two were compatible, and two were 
not compatible on H&E with the diagnosis of shHCA. 
These four cases could be classified as “true” UHCA. 
Five other cases could not be classified because (1) 
ASS1 positivity was not different between T and NT 
liver in three cases (although H&E was in two cases 
compatible and even typical), (2) there was not enough 
T liver to correctly interpret H&E and ASS1 staining 
due to the presence of massive bleeding in another case, 
and (3) there was not enough NT tissue in the last case.
Diagnosis on Biopsies By iHC
We selected biopsies that were negative for GS 
and CRP/SAA and with normal LFABP expression, 
in which we had enough T and NT tissue to reliably 
interpret H&E and ASS1 staining. There were 10 
biopsy cases from the CHU Bordeaux: five before a 
resection (cases 121, 162, 178, 191, and 235] and five 
others (Supporting Table S5). We had five additional 
biopsies: one case from Bordeaux consultation and 
four from the international study not linked to surgi-
cal cases (one that we requested after reading a case 
report of UHCA that appeared to us as a candidate 
of shHCA(28)). Clinical information is presented in 
Supporting Table S5. In all of these biopsies (those 
preceding resections were read without this indi-
cation), there was an overexpression of ASS1 in T 
fragments, in comparison to NT liver (Fig. 5A).
measuRement oF ass1 
Quantity in tHe seRa oF 
patients WitH HCa
We tested the possibility of identifying the shHCA 
subtype in a noninvasive manner. Using an ELISA 
strategy, we measured ASS1 quantity in the serum 
of patients corresponding to different HCA subtypes 
(13 IHCAs, 7 H-HCAs, 2 b-HCAs, 2 b-IHCAs, and 
Fig. 4. IHC results with anti-ASS1 antibody on the whole cohort of 67 patients: the three different series (A), in comparison with H&E 
classification (B), and global result in 67 UHCAs (C).
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4 shHCAs) (Supporting Fig. S5). Surprisingly, high 
amounts (0.19-2.31 ng/mL) of ASS1 were measured 
in all patients’ sera. The amounts were no higher in 
patients with shHCA as compared with the other 
cohorts. Thus, quantification of the amount of ASS1 
in serum is not an option to be considered.
mass speCtRometRy, an 
innoVatiVe tool to Complete 
Diagnosis oF shHCa
As shown in Fig. 1, we were able to quantify the 
T and NT ASS1 expression ratios by proteomic anal-
ysis on fixed tissue.(20,28) From there, we found that 
proteomic analysis by mass spectrometry could be an 
option to support shHCA diagnosis in case of uncer-
tain interpretation of ASS1 overexpression, especially 
on biopsies. As a proof of concept, using the fixed 
tissue, a proteomic analysis process was set up in the 
laboratory,(20,29) where we analyzed two biopsies: one 
typical and the other an ASS1 overexpression that was 
not clear-cut between T and NT tissue using IHC 
(Fig. 5B). In the latter case, the quantification of ASS1 
T:NT ratio and reference biomarkers resolved any 
ambiguity to assess an ASS1 overexpression (Fig. 5B).
Discussion
aDVantages anD limitations 
oF moleCulaR Biology FoR 
shHCa Diagnosis
The molecular subgroup shHCA is defined by a 
focal deletion that fuses the promoter of INHBE with 
Fig. 5. Biopsies of shHCA. (A) Biopsies with typical ASS1 IHC. ASS1 is clearly overexpressed in T compared with NT in two different 
fragments (case BinP1) or in the two parts (line) of the same biopsy (Case BCo1). (B) Biopsies analyzed by mass spectrometry–based 
proteomic. ASS1 is clearly overexpressed in T compared with NT fragments in case B162 with a high T:NT ASS1 ratio; ASS1 is quite 
difficult to interpret in biopsy BBDX3, but ASS1 (and other biomarkers) T:NT ratios quantified by mass spectrometry allowed us to assess 
the diagnosis of shHCA. Representative T and NT zones have been magnified. Abbreviation: NI, nonidentified.
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GLI1. This fusion can be detected either by amplifica-
tion on the cDNA (retro transcription of mRNA) or 
by RNA-sequencing analysis or quantitative RT-PCR 
of a targeted signature of four genes.(18) Due to its 
position downstream of the microdeletion, GLI is the 
direct molecular marker of shHCA. Through molec-
ular analysis of 20 patients with UHCA from the 
Bordeaux collection, we demonstrated a perfect con-
comitance between GLI1 and ASS1 overexpression, 
allowing us to conclude that ASS1 was a good marker 
to identify shHCA. However, it should be noted that 
detection of the deletion could only be confirmed in 12 
cases of the 18 tumors overexpressing GLI1. Similarly, 
Nault et al. reported the detection of INHBE-GLI1 
fusions in 15 of 20 shHCAs, despite a typical pattern 
of gene expression in all cases. It is possible that not 
all configurations of the focal deletions fused to the 
promoter of INHBE with GLI1 have been consid-
ered. We also demonstrated that PTGDS, part of the 
molecular signature that has been proposed,(18) is not 
strictly associated with shHCA.
In clinical routine, the diagnosis is essentially 
made by IHC with corresponding immunomark-
ers. Until now, the UHCA subgroup was defined 
by default, with all specific HCA markers being 
negative. The identification of two potential immu-
nomarkers brought the possibility of a more robust 
diagnosis of a subgroup of UHCA. PTGDS was not 
sensitive enough. In other words, PTGDS negativ-
ity does not exclude the diagnosis of shHCA. The 
anti-ASS1 antibody appeared to be more powerful, 
allowing the identification of 23 shHCAs from our 
collection of 24 UHCAs.
Concerning our functional study, in light of our 
results and those previously shown,(19) the molecu-
lar link between ASS1 and GLI or INHBE is not 
direct but cannot be excluded. An in vitro model 
of HCA cells in culture would probably be more 
relevant for functional analysis and would be worth 
developing.
shHCa in tHe HCa 
ClassiFiCation
Our goal was to use ASS1 overexpression as a 
marker to identify shHCA among UHCAs. Based 
on 58 cases representing the largest shHCA series, 
the characteristics of this HCA subgroup can be 
summarized as follows. It occurs essentially, if not 
exclusively, in women. Most are over 35 years old, 
on long-term OCs, overweight, with a steatotic 
liver, and often with clinical features of metabolic 
syndrome (e.g., arterial hypertension, diabetes, dys-
lipidemia). If the number of nodules as well as their 
size are not discriminant, the admission criteria are 
in part rather unique. Indeed, the admission rate 
for acute bleeding is particularly high (26% patients 
admitted in emergency for bleeding grade 1-3; 
30% and 43.5% if we add patients with pain and 
bleeding grade 2 or 1, respectively). If the identifi-
cation is made in daily routine based on the over-
expression of ASS1 in T compared to NT liver, the 
H&E criteria are essential. It is a nonencapsulated, 
monotonous, “bland,” well-differentiated hepatocel-
lular proliferation made of packed, often clear cells, 
often intermingled with areas of retracted hepato-
cytes with condensed nuclei, possibly related to 
ischemic suffering. The tumors are well vascularized 
by numerous isolated arteries and veins, often with 
the presence of hemorrhagic area, congestion, some-
times fibrotic bands, without noticeable inflamma-
tion, ductular reaction, or steatosis. The presence of 
cavities, often close to abnormal arteries and veins, 
of various sizes, solitary or grouped, with or with-
out blood at different stages of degradation (peliosis, 
red blood cells ghosts, loose fibrosis) is quite fre-
quent.(30) One important observation is the presence 
of bleeding (i.e., small hematoma) in small shHCAs 
(<5 cm), discovered in a resected specimen for large 
hemorrhagic shHCA.
ass1 impliCation in CliniCal 
pRaCtiCe
In most cases, HCAs are easily classified as 
H-HCA, IHCA, and b-HCA/b-IHCA. The dif-
ferent b-HCA/b-IHCA subtypes (exon 3 or exon 
7/8) may require molecular analysis, possibly per-
formed on formalin-fixed paraffin-embedded tissue 
(FFPET). If all HCA markers are negative, ASS1 
IHC is mandatory.
shHCAs represent 10% of surgical cases at our 
institution, which is higher than the previously pub-
lished multicentric French study (4%).(18)
The interpretation of the staining is not always 
clear-cut, like most immunomarkers, and the analy-
sis requires experience and a strict comparison with 
NT liver; nonobservance of this rule may lead to 
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misinterpretation of results. In a recent paper, ASS1 
IHC positivity (without comparison to NT liver in 
57% of cases) was not found to correlate with hem-
orrhage, whatever the HCA subtype.(21) It is quite 
obvious that all HCA subtypes can bleed. In this 
work, our purpose was to identify, using ASS1 over-
expression, shHCA that are known to be at high 
risk of bleeding.(18,20)
In four of five cases, ASS1 staining was noncon-
tributory, although they were compatible on H&E 
with shHCA. First, it is important to be sure that 
the case is not a classified HCA subtype (H-HCA, 
IHCA, b-HCA, b-IHCA). As mentioned in our first 
study,(20) the expression of ASS1 is not restricted 
to shHCA. In contrast, the ASS1 overexpression in 
tumor, in comparison to the NT liver, is a hallmark 
of shHCA.
To rule out difficulties of interpretations, we rec-
ommend, if necessary, to perform ASS1 on several 
blocks as well as in the NT liver far away from the 
tumor. We must emphasize that in most cases, the 
diagnosis of shHCA is straightforward and reinforced 
by the clinico-pathological data.
Additional techniques such as DNA and RNA 
sequencing, and proteomic analyses, are necessary to 
resolve the difficulties of interpretation. Our experi-
ence on biopsy is limited and, although preliminary, 
the results are promising.
shHCa management
This subgroup associated with high risk of signif-
icant clinical bleeding(18,20) and presence of hemor-
rhagic pathological criteria requires careful analysis. 
Fig. 6. Algorithm for shHCA diagnosis.
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These data will be useful to propose, in a defined 
clinical context (women, obesity/metabolic syndrome, 
age over 40, long-term OCs), the best options for 
management, to avoid emergency admission for acute 
severe HCA bleeding, independently of the tumor 
size (≤and ≥ 5 cm). In addition, it is possible to pro-
pose an algorithm to diagnose shHCA (Fig. 6).
uHCa Cases
Few cases were negative for all HCA markers, 
including ASS1. Interestingly, two of the four cases 
in our series that were compatible with shHCA on 
H&E were indeed ASS1-negative. This suggests 
that ASS1 is a mandatory marker to identify shHCA 
in daily practice, once the other HCA immunomark-
ers are established as negative. Again, it is crucial to 
eliminate other subtypes, particularly the b-HCA 
exon 7/8 mutated (in which GS staining can be very 
faint(30)), which can be wrongly interpreted as UHCA 
by an inexperienced pathologist requiring molecular 
analysis of b-catenin (possible on FFPET). If rare 
UHCA cases do exist, they remain a subject for fur-
ther study.
otHeR teCHniCal options 
FoR Diagnosis
We tested the possibility of measuring ASS1 in 
patient’s sera as a noninvasive test. ASS1, a key pro-
tein in hepatic pathophysiology, is present in high 
quantity and is detectable in all patients, without any 
possibility of identifying shHCA cases. Therefore, we 
have excluded measuring serum ASS1 as a diagnostic 
tool.
In case of difficulty, it is recommended to perform 
proteomic analysis on paraffin sections or molecular 
analysis (if frozen material is available).
Proteomic analysis is particularly promising on 
biopsy, provided that NT liver is available for compar-
ison. Based on the cases we analyzed by mass spec-
trometry, we set a threshold for overexpression as 1.5 
or greater. In the future, imaging data combined with 
biopsy results will help to identify HCA subtypes 
before surgery.
In conclusion, ASS1 overexpression is an addi-
tional tool for HCA classification of shHCA, a sub-
type known to be at high risk of bleeding. This HCA 
subgroup with well-defined clinical and pathological 
characteristics represents 10% of all HCAs. Combining 
IHC and proteomic analysis, ASS1 will allow identi-
fication of shHCA in practice.
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